SM04646

Developed for: idiopathic pulmonary fibrosis
Investigated by: Biosplice Therapeutics, Inc.

Trials 1

today NCT03591926 · Ph 2

18971898189919001901190219031904190519061907190819091910191119121913191419151916191719181919192019211922192319241925192619271928192919301931193219331934193519361937193819391940194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT03591926	Jan 1900	idiopathic pulmonary fibrosis	Biosplice Therapeutics, Inc.	Withdrawn	No outcome recorded Stop: Enrollment

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	SM04646	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03591926 ↗
Route	Inhaled	“Nebulized, inhaled solution” NCT03591926 ↗